Literature DB >> 22137663

Association between sRAGE, esRAGE levels and vascular inflammation: analysis with (18)F-fluorodeoxyglucose positron emission tomography.

Sae Jeong Yang1, Sungeun Kim, Soon Young Hwang, Tae Nyun Kim, Hae Yoon Choi, Hye Jin Yoo, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Sei Hyun Baik, Dong Seop Choi, Kyung Mook Choi.   

Abstract

BACKGROUND: The receptor for advanced glycation end-products (RAGE) and its diverse ligands play a pivotal role in the development of cardiovascular disease. Soluble forms of RAGE (sRAGE), including the splice variant endogenous secretory RAGE (esRAGE), may neutralize AGE-RAGE mediated vascular damage by acting as a decoy. (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a novel imaging technique for detecting vascular inflammation.
METHODS: We examined vascular inflammation measured using FDG-PET in 41 type 2 diabetes patients and 41 healthy control subjects in the right carotid artery. Vascular (18)F-FDG uptake was measured as the blood-normalized standardized uptake value (SUV), known as the target-to-background ratio (TBR). In addition, their relationship with carotid intima-media thickness (CIMT), estimated GFR (eGFR), and other cardiovascular risk factors was evaluated.
RESULTS: Both mean and maximum TBR values were significantly higher in patients with type 2 diabetes compared to healthy subjects. After adjusting for age and gender, sRAGE levels were significantly correlated with both mean and maximum TBR values, but not with CIMT values. Multiple linear regression analysis showed that maximum TBR values were independently associated with sRAGE levels in addition to HbA1c and eGFR.
CONCLUSIONS: Circulating sRAGE showed significant association with TBR values measured using FDG-PET, which reflect vascular inflammation.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22137663     DOI: 10.1016/j.atherosclerosis.2011.11.008

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

1.  Subclinical vasculitis as a potential mechanism to explain the heightened cardiovascular risk in rheumatoid arthritis.

Authors:  Zahi A Fayad; Jeffrey D Greenberg; Jan Bucerius
Journal:  Circulation       Date:  2012-10-24       Impact factor: 29.690

Review 2.  Glyco-oxidation and cardiovascular complications in type 2 diabetes: a clinical update.

Authors:  Francesco Piarulli; Giovanni Sartore; Annunziata Lapolla
Journal:  Acta Diabetol       Date:  2012-07-05       Impact factor: 4.280

3.  Variability in quantitative analysis of atherosclerotic plaque inflammation using 18F-FDG PET/CT.

Authors:  Karel-Jan D F Lensen; Alper M van Sijl; Alexandre E Voskuyl; Conny J van der Laken; Martijn W Heymans; Emile F I Comans; Mike T Nurmohamed; Yvo M Smulders; Ronald Boellaard
Journal:  PLoS One       Date:  2017-08-11       Impact factor: 3.240

4.  Endogenous Secretory Receptor for Advanced Glycation End Products Protects Endothelial Cells from AGEs Induced Apoptosis.

Authors:  Guomin Yang; Yinqiong Huang; Xiaohong Wu; Xiahong Lin; Jinting Xu; Xiaoyu Chen; Xuefeng Bai; Qiulan Li
Journal:  Biomed Res Int       Date:  2018-04-10       Impact factor: 3.411

5.  sRAGE and risk of diabetes, cardiovascular disease, and death.

Authors:  Elizabeth Selvin; Marc K Halushka; Andreea M Rawlings; Ron C Hoogeveen; Christie M Ballantyne; Josef Coresh; Brad C Astor
Journal:  Diabetes       Date:  2013-02-08       Impact factor: 9.461

6.  Positive association between serum level of glyceraldehyde-derived advanced glycation end products and vascular inflammation evaluated by [(18)F]fluorodeoxyglucose positron emission tomography.

Authors:  Nobuhiro Tahara; Sho-ichi Yamagishi; Masayoshi Takeuchi; Akihiro Honda; Atsuko Tahara; Yoshikazu Nitta; Norihiro Kodama; Minori Mizoguchi; Hayato Kaida; Masatoshi Ishibashi; Naofumi Hayabuchi; Takanori Matsui; Tsutomu Imaizumi
Journal:  Diabetes Care       Date:  2012-08-21       Impact factor: 19.112

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.